1 54

IJMMS_2024v14n3

1 Introduction 6
2 Current State of Xenotransplantation 7
2.1 Definition and historical background 7
2.2 Current challenges in xenotransplantation 7
2.3 Overview of donor species and recipient compat 8
3 CRISPR/Cas9 Technology 8
3.1 Principles and mechanisms of CRISPR/Cas9 8
3.2 Advantages of CRISPR/Cas9 Over traditional gen 8
3.3 Applications of CRISPR/Cas9 in medical researc 9
4 Applications of CRISPR/Cas9 in Xenotransplantati 11
4.1 Genetic modification of donor animals to reduc 11
4.2 Prevention of zoonotic disease transmission th 11
4.3 Enhancing organ compatibility and function 11
4.4 Case studies and successful experiments using 11
5 Ethical and Regulatory Considerations 12
5.1 Ethical concerns surrounding genetic modificat 12
5.2 Regulatory frameworks governing the use of CRI 12
5.3 Public perception and acceptance 13
6 Technical Challenges and Limitations 13
6.1 Off-target effects and genetic stability 13
6.2 Long-term viability and functionality of edite 13
6.3 Challenges in scaling up from laboratory to cl 14
7 Future Directions and Opportunities 14
7.1 Emerging technologies and advancements in CRIS 14
7.2 Potential breakthroughs in immunosuppression a 14
7.3 Integration of CRISPR/Cas9 with other biotechn 14
7.4 Long-term vision for xenotransplantation and i 14
8 Concluding Remarks 15
1 Introduction 28
2 Background on Xenotransplantation 29
2.1 Definition and historical context 29
2.2 Current advancements and breakthroughs in xeno 30
2.3 Comparison of xenotransplantation with allotra 30
3 Immunological Barriers in Xenotransplantation 30
3.1 Host immune response to xenografts 30
3.2 Hyperacute rejection, acute vascular rejection 31
1)Hyperacute rejection: 31
2) Acute vascular rejection: 31
3) Chronic rejection: 32
3.3 Role of genetic modifications in overcoming im 32
4 Key Genetic Determinants for Graft Survival 32
4.1 Genes involved in immune evasion and tolerance 32
4.2 Genetic modifications to reduce antigenicity 33
4.3 Genes enhancing organ resistance to rejection 33
5 CRISPR/Cas9 and Genetic Engineering in Xenotrans 33
5.1 Overview of CRISPR/Cas9 technology and its app 33
5.2 Case studies of CRISPR/Cas9-mediated genetic m 33
5.3 Potential and limitations of CRISPR/Cas9 for i 34
6 Mechanisms of Genetic Modifications for Graft Su 34
6.1 Mechanisms reducing hyperacute rejection 34
6.2 Mechanisms mitigating acute vascular and cellu 34
6.3 Enhancing long-term graft survival through gen 35
7 Ethical and Regulatory Considerations 35
7.1 Ethical issues related to genetic engineering 35
7.2 Regulatory frameworks for genetic modification 35
7.3 Public perception and acceptance of geneticall 35
8 Case Studies and Clinical Trials 36
8.1 Analysis of successful case studies in pig-to- 36
8.2 Ongoing and future clinical trials focusing on 37
8.3 Outcomes and lessons learned from clinical app 38
9 Challenges and Future Directions 38
9.1 Technical challenges in achieving long-term gr 38
9.2 Emerging trends and innovative approaches 39
9.3 Interdisciplinary research and collaboration o 39
10 Concluding Remarks 39
1 Introduction 44
2 Overview of Sickle Cell Anemia 45
2.1 Genetic and molecular basis 45
2.2 Pathophysiology and symptoms 45
2.3 Epidemiology and global impact 45
3 Fundamentals of Gene Editing Technologies 46
3.1 CRISPR-Cas9 technology 46
3.2 Other Gene editing tools 46
3.3 Base and prime editing 46
4 Applications of Gene Editing in Sickle Cell Anem 46
4.1 Gene editing in hematopoietic stem cells 46
4.2 Animal models of sickle cell anemia 47
4.3 Successes in preclinical trials 47
5 Clinical Trials and Advances 48
5.1 Current clinical trials 48
5.2 Case studies 48
6 Challenges and Barriers to Implementation 49
6.1 Technical challenges 49
6.2 Ethical and regulatory issues 49
6.3 Socioeconomic barriers 49
6.4 Regulatory and safety evaluations 50
7 Future Perspectives 50
7.1 Technological advancements 50
7.2 Combining therapies 50
7.3 Long-term vision 50
8 Concluding Remarks 50

RkJQdWJsaXNoZXIy MjQ4ODYzNQ==